Haematology

Mayo Alliance Prognostic System for Systemic Mastocytosis calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Advanced systemic mastocytosis

Age

years

Allowed range: 18–100 years

Older than 60 years scores 1. Age 60 does not.

Platelets

/µL

Allowed range: 1000–2000000 /µL

Below 150×10^9/L scores 1. A count of exactly 150 does not.

Alkaline phosphatase above the reference rangeAdverse mutation

Result

2 fields remaining

Anyone can run this calculator. Sign in to save, favourite, or send the result.

Professional use only

For qualified clinicians. Independently verify inputs, calculations, source guidance, and applicability before any clinical action. This calculator does not replace clinical judgment.

Source: Pardanani A et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. DOI: 10.1182/bloodadvances.2018026245. PMID: 30413432. Figure 3 assigns 2 points for advanced systemic mastocytosis versus indolent or smoldering disease, and 1 point each for age >60 years, platelets <150×10^9/L, alkaline phosphatase above the reference range, and an adverse mutation in ASXL1, RUNX1, or NRAS. Low risk is 2 points or fewer (median survival 198 months), intermediate-1 is 3 points (85 months), intermediate-2 is 4 points (36 months), and high risk is 5 points or more (12 months). (2018)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

Advanced systemic mastocytosis
Age (years)Accepted range: 18 to 100
Platelets (×10^9/L)Accepted range: 1 to 2000
Alkaline phosphatase above the reference range
Adverse mutation

Primary source

Pardanani A et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. DOI: 10.1182/bloodadvances.2018026245. PMID: 30413432. Figure 3 assigns 2 points for advanced systemic mastocytosis versus indolent or smoldering disease, and 1 point each for age >60 years, platelets <150×10^9/L, alkaline phosphatase above the reference range, and an adverse mutation in ASXL1, RUNX1, or NRAS. Low risk is 2 points or fewer (median survival 198 months), intermediate-1 is 3 points (85 months), intermediate-2 is 4 points (36 months), and high risk is 5 points or more (12 months). (2018)

View source